Hepatology

Filter

Novel Non-Invasive Liver Fibrosis Tests Are Effective Biopsy Alternatives

February 2026

Novel non-invasive liver disease assessments (NILDAs) are effective liver biopsy alternatives for fibrosis, a 2026 systematic review has found.

Mitigation of Immune Dysfunction in Patients with Hepatitis B after siRNA Treatment

A chronic hepatitis B (CHB) infection is characterised by host immune dysfunction related to a high viral antigen load. The restoration of…

Albumin Therapy for Decompensated Cirrhosis: EASL Congress 2025

THE MANAGEMENT of decompensated cirrhosis remains a formidable challenge in hepatology, owing to its multifaceted complications…

Hepatocyte–Neutrophil Interaction Is Key in the Pathogenesis of Alcohol-Associated Hepatitis

Alcohol-associated hepatitis (AH) is the most severe form of alcohol-related liver disease (ALD), which is characterised by an impairment…

EASL 2025 Abstract Highlights

The following highlights showcase late-breaking research presented at the European Association for the Study of the Liver (EASL) Congress…

Pregnancy and Liver Disease: A Multidisciplinary Challenge

AT THIS year’s European Association for the Study of the Liver (EASL) Congress 2025, held in Amsterdam, the Netherlands…

Combination Therapy Improves Survival in Liver Cancer

Results showed that patients receiving the combination therapy experienced a median progression-free survival of 5.8 months, compared with 4.0 months.

Non-Diabetic Metabolic Dysfunction Increases Liver Fibrosis Risk

This study explored the effects of various metabolic abnormalities, such as central obesity, high blood pressure, and elevated high-sensitivity C-reactive protein (hsCRP), on liver steatosis and fibrosis.

Reducing Alcohol Consumption to Prevent Liver Disease Globally

Discover more about strong evidence that public health measures, such as raising alcohol prices and restricting access can significantly reduce alcohol consumption.

Loading posts...

« Previous 1 … 14 15 16 17 18 … 76 Next »